Chen et al(61) showed that treatment with the PXR agonist SR12813 activated PXR in breast cancer cell lines and increased the expression of MDR1 and CYP3A4 and the resistance of cells to paclitaxel, vinblastine and tamoxifen. Here, CYP3A4 is linked to breast cancer.